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Background – Equine sarcoids are the most prevalent skin neoplasm in horses worldwide. Although several
treatments are available, none are consistently effective and recurrence is common.
Objectives – To evaluate the efficacy and safety of topical imiquimod 5% cream and Sanguinaria canaden-
sis + zinc chloride for treatment of equine sarcoids and investigate possible systemic effects on distant
untreated sarcoids.
Animals/Tumours – Twenty-five client-owned horses with a total of 164 tumours were included in the study.
Fifty-seven tumours were treated and 107 tumours were left untreated.
Methods and materials – Skin biopsy samples were collected from a minimum of one tumour per horse and
the rest were diagnosed based on clinical appearance as likely sarcoids. Imiquimod 5% (A) was applied three
times weekly, while Sanguinaria canadensis + zinc chloride (X) was applied every fourth day after a six day daily
initiation phase. Treatment continued until clinical remission or for a maximum of 45 weeks, with a long follow-
up period (mean 34 months). Skin biopsy samples of sarcoid lesions were re-taken before treatment termination
and at follow-up if the owner gave consent.
Results – Complete remission was recorded in 84.4% (A) and 75.0% (X) of the tumours. Relapse was recorded
in 7.3% (A) and 21.4% (X). Spontaneous remission was observed in 1.9% of untreated tumours. No systemic
effect on untreated tumours was detected. During treatment varying degrees of local inflammatory reaction
were common.
Conclusions and clinical relevance – Both treatments were considered effective and safe. Smaller tumours
responded more favourably to treatment. Relapse rate was low and not observed in sarcoids with repeat biopsies
before treatment termination.
Introduction
Sarcoids are the most common skin tumours seen clini-
cally in horses worldwide.1–4 The tumours are prolifera-
tive, fibroblastic and have variable epithelial components.
Most studies have shown that sarcoids rarely resolve
spontaneously.1,5–8 Although sarcoids are nonmetastatic,
their size, spread, location, affected area and sometimes
locally invasive growth can impair the use and value of
the horse, and even lead to it being euthanized. The aeti-
ology is multifactorial, including viral and genetic fac-
tors.1,2 Several studies have demonstrated an association
with bovine papillomavirus (BPV types 1 and 2).9,10 The
bovine papillomavirus has been shown to be able to trans-
form equine fibroblasts in vitro,11 and the presence of
BPV-DNA in surgical margins has been associated with a
high rate of relapse.12,13 Several treatment options are
available,14–20 although none is universally effective and
safe. Sarcoids are well-known for a high rate of relapse
post-treatment.2,6,18
Imiquimod 5% (Aldara, 3M Health Care Limited;
Loughborough, UK) is an immune response modifier
approved for topical use in humans, with potent antivi-
ral and antitumour activities. Both the innate and
acquired immune systems are activated via TLR7,
inducing a Th1 cytokine response [interleukin (IL)-2, IL-
12, interferon (IFN)-a and IFN-c] and increases in the
levels of tumour necrosis factor (TNF)-a, IL-1, IL-6 and
IL-8. Lymphocytes, macrophages and dendritic cells
are attracted to the treated area.21 Successful treat-
ment of human genital warts caused by human papillo-
mavirus has been reported.22 The drug also has been
reported to be beneficial in the treatment of equine
sarcoids.23
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Sanguinaria canadensis + zinc chloride (Xxterra, Lar-
son Laboratories DBA Vetline Equine, Inc.; Fort Collins,
CO, USA) is an unregistered herbal ointment containing
a zinc chloride solution and an extract from the blood-
root plant (Sanguinaria canadensis). Bloodroot contains
sanguinarine, chelarathrine and protopine, all of which
are alkaloids. Sanguinarine has antibacterial, antifungal,
anti-inflammatory and anti-platelet activities.24–27 San-
guinarine also has a suppressive effect on angiogene-
sis,28 and induces cell cycle arrest or apoptosis in mice
and human cancer cells.29–32 In addition, sanguinarine
has been demonstrated to induce necrosis and apopto-
sis in KB cancer cells, which are keratin-producing
tumour cells containing sequences from human papillo-
mavirus 18 (HPV-18).33 Sanguinarine interacts with DNA
via intercalation, and its binding impairs DNA poly-
merase, inducing DNA strand breaks and cell death.34
BPV, vascular endothelial growth factor (VEGF),
increased angiogenesis and growth of tumour cells are
strongly associated with the pathogenesis of sarcoid
disease,9,10,35 which presumptively make bloodroot a
suitable treatment option.
The purpose of this clinical study was to evaluate the
efficacy and safety of topical imiquimod 5% cream, and
Sanguinaria canadensis + zinc chloride treatment of
equine sarcoids and to investigate any possible systemic




The study protocol was given ethical approval by the Research Ani-
mal Ethics Committee of the Swedish Board of Agriculture (no. 167/
10), Uppsala, Sweden. Informed written owner consent was
obtained for each case, and the owner had the right to withdraw the
horse from the study at any time.
Inclusion criteria
Client-owned horses of any breed, sex and age with one or more
lesions compatible with the diagnosis of equine sarcoids were
included in the study (Table 1). Biopsies of at least one tumour
per horse were taken and histopathologically confirmed as a sar-
coid before enrolment. Horses appeared healthy on clinical exami-
nation and were reported not to be pregnant by their owner.
Before enrolment, horses had not received any sarcoid treatment,
including topical and systemic corticosteroids, for at least one
month. The study was advertised in different media. Horses
meeting the study inclusion criteria were enrolled between March
2007 and March 2009.
Animals and tumours
Tumours were divided into two groups (1 or 2) according to diagnos-
tic method:
Group 1: Histopathologically confirmed sarcoids; all treated to
reduce the risk of aggressive growth after biopsy was taken.10,36–38
Group 2: Likely sarcoids based on their clinical appearance; classi-
fied according to a published clinical classification.8
The tumours then were assigned randomly (by lot drawing) to
treatment Category A (Imiquimod 5%) or Category X (Sanguinaria
Table 1. Characteristics of the 26 horses and 167 tumours enrolled in the study
Horse Sex Breed Number of sarcoids Tumour type Age at onset (years) Previous treatment
Response to
previous treatment
1 M SWB 13 V, F, N, M 5 Surgery Relapse
2 G Standardbred 1 F 2½ None –
3 M SWB 7 F NA None –
4 G SWB 1 M 4 None –
5 G SWB 1 F 2 None –
6 G SWB 1 N 13 None –
7 G SWB 6 O, V, F, M 3 None –
8 G Connemara pony 28 O, N, F, M NA Surgery Relapse
9* G SWB 3 N 12 None –
10 G Hanoverian 12 O, F NA None –
11 G Pony 15 F, N, O NA Surgery Relapse
12 G Icelandic horse 1 N 7 Surgery Relapse
13 M New Forest pony 15 O, N, M, F 3 Xxterra Relapse
14 G Standardbred 2 F, N 7½ Steroid No response
15 G Arabian 14 O, V, F, M 3 None –
16 M SWB 19 M, O, F, N NA None –
17 G SWB 4 O, M NA None –
18 G Arabian 6 F, O, M 8 None –
19 G SWB 1 M 8 None –
20 M SWB 1 M NA None –
21 G SWB 1 F 3 None –
22 M Icelandic horse 1 F NA None –
23 G Pura Raza Espanôl 1 M 3 Xxterra Relapse
24 M Standardbred 7 N, O 12 None –
25 G SWB 5 N NA None –
26 M Arabian 1 N 8 None –
Sex: M mare; G gelding.
Breed: SWB Swedish warmblood.
Tumour type: O occult, N nodular, F fibroblastic, V verrucous, M mixed type.
NA not available.
*Excluded before treatment because histopathological evaluation revealed other diagnosis (eosinophilic granuloma).
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(1 change of 
treatment)
Category A: Imiquimode 5%
Category X: Sanguinaria 
canadensis and zinc chloride
Category C: Untreated 
control group
* Tumours 1b and 10c reported in both groups A and X. ** Tumours 1a and 1c reported in both groups A and X
Figure 1. Overview of study organization of enrolment of horses and tumours into sarcoid groups, treatment categories and their treatment out-
comes.
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canadensis + zinc chloride). All facial tumours were assigned to Cat-
egory A, because Xxterra is not recommended for use on the ears or
in the periocular area, according to the product information and anec-
dotal evidence. A third category (C) was designated for tumours left
untreated and used to detect potential systemic effects on distant
sarcoids in horses with multiple tumours, and to determine the rate
of spontaneous remission (Figure 1).
This study was nonblinded. Selection criteria for treatment (cate-
gories A or X) or allocation to Category C (left untreated) included
impact of tumours on usage of the horse, location, type of sarcoid
coverage and the horse owner’s financial constraints. The horses
were numbered consecutively and the tumours on each horse were
given a letter in alphabetic order, for example, Horse 1, Tumour 1a,
1b etc. Full data on each individual tumour are available in Tables S1
and S2.
One horse with three nodular sarcoid-like lesions was excluded
before treatment because histopathological evaluation revealed the
presence of eosinophilic granuloma (Horse 9; Table 1).
Treatment protocol
After the tumour was assigned to a treatment category, owners
were instructed with verbal and written treatment instructions. For
handling of tumours and medical products, rubber gloves were
strongly recommended.
For tumours in Category A, clients were to apply a thin layer of imi-
quimod 5% cream topically three times weekly on nonconsecutive
days.
For tumours in Category X, clients were to apply a thin layer of
Sanguinaria canadensis + zinc chloride topically every fourth day
after an initiation period of six days of daily treatment. If possible, the
treated area was to be covered with a bandage. Skin surrounding the
treatment area and skin that could come in contact with the treated
area was protected, either with a covering or with petroleum jelly.
Tumours in both categories were cleansed with chlorhexidine
digluconate 4% (Hibiscrub, Regent Medical Overseas Ltd; Irlam, UK)
and dried before treatment.
Treatment period was defined as the number of weeks from the
first to the last treatment of each individual tumour and continuing
until complete remission (tumour mass resolved or a smooth ulcer-
ated surface remaining) or a maximum of 45 weeks. Repeat biopsies
were taken of tumours macroscopically determined to be in remis-
sion before treatment termination and at follow-up if owners con-
sented. Biopsies were taken from the centre of the previous tumour
area. Where no response to treatment was recorded after 12 weeks,
the tumour was transferred to the other treatment group, after a 12-
week washout period. These tumours are recorded in both treatment
categories; therefore, the total number of treated tumours can
exceed the number of included tumours. The treatment period was
succeeded by the follow-up period, which continued until the last
monitoring of the horse.
Exclusion criteria
Histopathological diagnoses other than equine sarcoid, noncompli-
ance with the study protocol and clients wishing to withdraw
resulted in exclusion after recording the case.
Assessment of treatment efficacy, adverse effects
and follow-ups
At the first visit, information was collected on tumour description,
affected relatives, age when tumour was first identified and progres-
sion of tumour growth as perceived by the owner, and previous treat-
ments including responses to treatments. At all visits, a clinical
examination of the horse was performed, and tumours were mea-
sured with a ruler (height x length x width, in mm) and photographed.
Visits occurred consistently every four to six weeks during the treat-
ment period. Owners were interviewed for compliance and possible
adverse effects. Inflammatory reactions were evaluated and mea-
sured. The reaction was considered mild if swelling, erosion and
crusting extended <2 cm outside the original demarcated tumour,
moderate between 2 and 3 cm and severe >3 cm outside. The
reaction was always considered severe if a systemic reaction
occurred. If pain was reported, a nonsteroidal anti-inflammatory drug
(NSAID) or a short period of treatment withdrawal (a maximum of
Figure 2. Small tumour (occult sarcoid, head).
Figure 3. Medium tumour (nodular sarcoid, perineum).
Figure 4. Large tumour (fibroblastic sarcoid, distal limb).
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two weeks), were considered. Follow-up periods were between
December 2007 and May 2011, and performed by re-examination or
telephone interview.
Data treatment and statistical analysis
Tumours were grouped into numbers per horse (<3, 3–10, >10);
tumour size [<1,000 mm3, small (Figure 2); 1,000–9,999 mm3, med-
ium (Figure 3); >10,000 mm3, large (Figure 4)] and treatment dura-
tion (<10 weeks, 10–19 weeks, >19 weeks). Differences in the size
of the tumours at the start (categories A and X) and at the end of the
treatment period were investigated by ANOVA (proc GLM, SAS 9.2).
Post ANOVA comparisons between categories were analysed using
the Scheffe test. Comparisons between categories (A, X and C) were
performed using the GLM contrast option, including adjustments for
multiple comparisons. Similar procedures were used to test for dif-
ferences in duration of treatment in relation to the treatment cate-
gories. Among treated tumours (n = 61), the number of treatments
application was compared between the categories (ANOVA). The
treatment effect on changes in tumour size was evaluated by includ-
ing the number of tumours, size, type and duration of treatment
(three classes each) in the ANOVA model. Nonsignificant effects of
factors and/or interactions were removed from the models. Finally,
treatment outcome (complete remission, partial regression and no
remission) was analysed by log linear models (Proc LOGISTIC, SAS
9.2), including initial number of tumours, tumour size and treatment
duration (three classes each). Nonsignificant effects of factors and/or
interactions were removed from the models.
For continuous variables, the results are presented as the least
square means  standard error of the mean (SEM). Differences with
associated P-values <0.05 were considered significant.
Results
Treatment outcome
Twenty-five horses with a total of 164 tumours were
included in this study (Figure 1). In total, 45 tumours were
treated with imiquimod 5% cream (Category A) (Fig-
ure 5a–c), with 22 in Group 1 and 23 in Group 2. Sixteen
tumours were treated with Sanguinaria canadensis + zinc
chloride (Category X) (Figure 6a–c), seven in Group 1 and
nine in Group 2. Of the 32 treated tumours in Group 2,
13% were satellite lesions and 16% were lesions within
20 cm of the tumour from which a biopsy was taken.
After 12 weeks of treatment, three fibroblastic sar-
coids (A) and one occult sarcoid (X) were regarded as non-
responsive and transferred over to the other treatment
category (recorded in both categories). Three tumours
(1a, 1c, 10c) achieved full remission, whereas one tumour
(1b) was excluded due to surgery after a 52% reduction
in size. The mean volume of the three tumours in Cate-
gory A (1a, 1b, 1c) were larger (P < 0.05) than the mean
volume of the tumours in categories A, X and C.
More than 50% of the tumours in Category X were
large, those in Category A were more varied in size and
approximately 70% in Category C were small. The pre-
treatment tumour volumes were larger in categories A




Figure 5. Sarcoids treated with imiquimod 5% cream.
Histopathologically verified fibroblastic and nodular sarcoids in the perineal area, before treatment (a), after five weeks of treatment (b) and at three
year follow-up (c). Scar tissue is evident. Adjacent tumours also responded to treatment.
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tumours had a greater chance of complete remission than
large tumours (P < 0.05).
The treatment duration varied between four and
45 weeks (mean 16.6 weeks, median 13.5 weeks) in
Category A, and between four and 38 weeks (mean
12.1 weeks, median 9.5 weeks) in Category X. Category
A was composed of 12 occult, nine nodular, one verru-
cous, eight mixed and 15 fibroblastic sarcoids; the
tumours were located on the head (27) (including six peri-
ocular, four on the ear), axilla (four), distal limb (three),
trunk (five), genitalia (five) and neck (one). Category X
was composed of one occult, three nodular, two verru-
cous, two mixed and eight fibroblastic sarcoids, located
on the limbs (five), trunk (four), genitalia (four), axilla (two)
and neck (one). (Full individual tumour data, including
results, are available in Tables S1 and S2). A majority of
the included horses (14 of 25) had multiple lesions (two
to 28, mean 10.8, median 9.5) that were compatible with
the diagnosis of being sarcoids (Table 1). In all but one
horse with multiple tumours, more than one clinical type
of sarcoids was present.
Complete tumour remission was recorded in 38 of 45
tumours in Category A (18 in Group 1 and 20 in Group 2)
and 12 of 16 tumours in Category X (four in Group 1 and
eight in Group 2) (Figures 8 and 9). In fibroblastic sarcoids
complete remission was recorded in 80% with either
treatment protocol. There was no difference in complete
remission between the two treatment categories
(P < 0.05). Categories A and X had a higher chance of
resulting in complete remission (P < 0.05) than Category
C. Treatment was the only factor that influenced remis-
sion (P < 0.05).
a b c
Figure 6. Sarcoid treated with Sanguinaria canadensis + zinc chloride.
Histopathologically verified fibroblastic sarcoid before treatment (a), after five weeks of treatment (b) and at three year follow-up when repeat
biopsy verified the clinical cure (9c). Scar tissue is evident.
Figure 7. Pre-treatment mean and median tumour volume (mm3) in categories A and X.
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The follow-up period was eight to 200 weeks (A, mean
154 weeks, median 151 weeks; X, mean 156 weeks,
median 160 weeks). Physical examination at follow-up
was possible in 16 (A) and eight (X) horses. Relapse was
recorded in three of 41 (A) and three of 14 (X) of the sar-
coids, all in Group 2. Relapse occurred in the same area
as the original tumour. There was no difference in the
relapse rate between the two treatment categories
(P < 0.05). Relapse was not detected in all sarcoids that
had been re-evaluated histologically before discontinua-
tion of treatment (seven of 55), and clinical cure could be
verified by evaluation of biopsy at follow-up.

















































Figure 8. Treatment Category A – type, group, size and results.
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Withdrawn tumours
Six of 61 tumours were withdrawn, four in Category A
and two in Category X (Figure 1). There was no differ-
ence in the total number of excluded tumours in cate-
gories A and X (P < 0.05). For four tumours, the
owner chose surgical removal of the lesion after
reductions in size (16.7–89.1%) after seven to
12 weeks of treatment. One owner did not follow the
treatment recommendations, and one decided to with-
draw from the study as the horse rejected treatment,
likely due to pain; oral NSAID treatment was offered
and declined.

















































Figure 9. Treatment Category X – type, group, size and results.
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Untreated sarcoids
Two (occult small) of 107 (1.9%) untreated tumours
regressed spontaneously during the treatment period;
thus, a reduction in tumour size was less likely (P < 0.05)
to occur in the untreated controls than in the tumours in
treatment categories A and X. During the treatment per-
iod, 99 (92.5%) sarcoids remained static and six (5.6%)
increased in size. In two horses with multiple tumours at
inclusion, novel sarcoids (occult) developed at distant
sites during the treatment period.
Local effects
All treated areas showed signs of inflammation which
were mild [38 of 45 (A), 11 of 16 (X)], moderate [four of 45
(A), three of 16 (X)] and occasionally severe [three of 45
(A), two of 16 (X)], in addition to varying degrees of ooz-
ing, exudation, erosion, crusting, swelling and pain. At fol-
low-up, five of the horses treated with Sanguinaria
canadensis + zinc chloride had residual scar tissue (Fig-
ure 6c), and six of the horses treated with imiquimod 5%
had alopecia, two had residual scar tissue (Figure 5c) and
one had hypopigmentation at the site of treatment. A
temporary (two week) discontinuation of treatment was
sufficient to resolve local pain in two horses; none
received NSAIDs.
Discussion
Today, there are few simple and effective treatment
options available for equine sarcoids, and many of them
carry a high risk of tumour relapse. This study showed
promising results with a low rate of tumour relapse.
Although treatments were easy to perform, they may
require a long treatment period, and local pain and inflam-
mation may occur during treatment.
The high rate of histopathological confirmation of sus-
pected sarcoids indicates a frequent occurrence of true
sarcoids, and also that clinical examination cannot fully
replace histopathological evaluation. Taking a biopsy
before treatment could be a risk factor for a worse prog-
nosis, because traumatizing a sarcoid has been reported
to induce more aggressive tumour growth.2,6,18 Treat-
ment was initiated promptly within 14 days for all sar-
coids from which biopsies were taken. A high response
rate was recorded in sarcoids from which biopsies were
taken, with complete remission in 81.5% (22 of 27),
including nine fibroblastic sarcoids. One fibroblastic sar-
coid reduced by 98.9% in size, and four were excluded
owing to surgical removal. Relapse was seen only in sar-
coids that were not evaluated histologically (Group 2).
Thus, taking a biopsy before treatment did not seem to
result in a worse prognosis if treatment was initiated at
diagnosis. In tumours from which biopsies were not
taken (Group 2) there was no confirmation of the diagno-
sis, which may represent a weakness in this study.
An earlier study of imiquimod 5% cream in the topical
treatment of equine sarcoids resulted in 56% complete
remission and 20% partial regression, with mean and
maximum treatment durations of 14.7 and 32 weeks,
respectively.23 In total, >80% of the tumours had a >75%
reduction in tumour size. In the current study, complete
remission was recorded in 84.4% of tumours in
treatment Category A; the higher response rate might be
a consequence of the longer treatment period, with mean
and maximum treatment durations of 16.6 and 45 weeks,
respectively.
A retrospective questionnaire-based survey on the effi-
cacy of Newmarket bloodroot ointment, a different for-
mulation of bloodroot, resulted in a complete remission in
66.2% or partial regression in 20.3%. Treatment duration
in that study was grouped according to total days of treat-
ment [<21 days (63.4%); 21–42 days (26.8%); >42 days
(9.8%)].39 In the current study, complete remission was
recorded in 75% of tumours in treatment Category X,
with mean and maximum treatment duration of 12.1 and
38 weeks, possibly reflecting a different treatment proto-
col and longer treatment period.
Treatment was discontinued upon macroscopic evi-
dence of curative treatment in most cases. The treatment
induced visible local inflammatory reactions, which made
the macroscopic assessment more difficult. A risk of both
overtreatment and undertreatment of the sarcoids there-
fore was possible and could have introduced bias. The
surrounding skin also reacted during treatment; this phe-
nomenon was more commonly noticed in those sarcoids
treated with imiquimod 5% cream. This may indicate that
tumour cells and BPV outside the macroscopically demar-
cated tumour also were affected by the treatment, and
may thus provide one explanation for the low relapse
rate. Mild to moderate tenderness and pain were
reported frequently when cleaning the area before treat-
ment. This usually occurred when most of the tumour
mass was gone and might reflect proximity to nerve end-
ings in the dermis.
Small tumours responded more favourably than large
tumours to any of the treatment categories. Fibroblastic
tumours responded well to both treatments, with a ten-
dency of fewer treatments in Category X. Occult tumours
responded well to imiquimod 5%. As most of the occult
tumours were located on the face, only one was treated
with Sanguinaria canadensis + zinc chloride. This tumour
did not respond to the treatment and was later trans-
ferred to the other treatment category. Nodular, verru-
cous and mixed sarcoids responded well to both
treatments. No pattern in treatment outcome associated
with location was detected. Interestingly, tumours that
did not respond to the initial treatment (four) achieved
complete remission (three) or a reduction in size (one)
when they were transferred to the other treatment cate-
gory. Size, type of sarcoid, location on the body and
immunity may have played a role.
Less than 2% of untreated tumours (Group 2) went into
spontaneous remission. Most studies have shown that
sarcoids rarely resolve spontaneously.1,5–8 However, a
recent study in young horses (sarcoid present by the age
of three years) found that 48% of milder sarcoids, occult
and verrucous types, disappeared without treatment
within five to seven years.40 In the current study, tumours
that went into spontaneous remission were occult and
the horses were seven (sarcoid present by the age of
three years) and six years old (no data on when sarcoids
appeared) when entering the study. These two horses
had multiple tumours and received treatment with both
ointments. The low number of spontaneous remissions in
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this study does not support the existence of a systemic
effect in any of the treatment protocols.
In conclusion, in this study, both imiquimod 5% cream
and Sanguinaria canadensis + zinc chloride were effec-
tive and safe for the topical treatment of equine sarcoids
and treatments could be applied by owners without diffi-
culty. These results are encouraging, despite the fairly
small sample size, and suggest that further studies are
warranted to substantiate the conclusions.
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Resume
Contexte – Les sarco€ıdes equins sont la tumeur cutanee la plus prevalente chez le cheval dans le monde
entier. Bien que plusieurs traitements soient disponibles, aucun n’est totalement efficace et les recidives
sont frequentes.
Objectifs – Determiner l’efficacite et l’innocuite de la creme imiquimod 5% et Sanguinaria canadensis +
chloride de zinc dans le traitement de sarco€ıdes equins et etudier les effets systemiques potentiels sur les
sarco€ıdes distants non traites.
Sujets/tumeurs – Vingt-cinq chevaux de proprietaires avec un total de 164 tumeurs ont ete inclus dans
l’etude. Cinquante-sept tumeurs ont ete traitees et 107 non traitees.
Materiels et methodes – Des biopsies ont ete prelevees, au moins une par cheval, les autres etaient diag-
nostiquees comme probablement des sarco€ıdes a partir de l’aspect clinique. L’imiquimod 5% (A) a ete
appliquee trois fois par semaine, tandis que Sanguinaria canadensis + chloride de zinc (X) a ete applique
tous les quatre jours apres une phase d’initiation d’une fois par jour pendant six jours. Le traitement a ete
poursuivi jusqu’a remission clinique ou pendant 45 semaines maximum, avec une periode de suivi longue
(34 mois en moyenne). Des biopsies des sarco€ıdes ont ete renouvelees apres la fin du traitement et en
suivi si le proprietaire donnait son consentement.
Resultats – Une remission complete a ete enregistree dans 84.4% (A) et 75.0% (X) des tumeurs. Une reci-
dive a ete observee dans 7.3% (A) et 21.4% (X). Une remission spontanee a ete observee dans 1,9% des
tumeurs non traitees. Aucun effet systemique indesirable sur les tumeurs non traitees n’a ete detecte. Au
cours du traitement des degres variables d’inflammation locale etaient frequents.
Conclusion et importance clinique – Les deux traitements sont consideres comme surs et efficaces.
Les plus petites tumeurs repondaient plus favorablement au traitement. Le taux de recidive etait faible et
non observee au sein des biopsies repetees apres la fin du traitement.
Resumen
Introduccion – los sarcoides equinos son la neoplasia cutanea mas prevalente en caballos en todo el mun-
do. Aunque hay varios tratamientos disponibles, ninguno es eficaz de manera constante y la recidiva es fre-
cuente.
Objetivos – Evaluar la eficacia y seguridad de la crema topica de imiquimod al 5% y Sanguinaria canaden-
sis + cloruro de zinc para el tratamiento de sarcoides equinos e investigar los posibles efectos sistemicos
en sarcoides distantes no tratados.
Animales/tumores – se incluyeron en el estudio veinticinco caballos de propietarios privados con un total
de 164 tumores. Se trataron cincuenta y siete tumores y se dejaron sin tratar 107 tumores.
Metodos y materiales – se tomaron biopsias de un mınimo de un tumor por caballo y el resto se diagnos-
tico basandose en la apariencia clınica como sarcoides probables. Se aplico imiquimod al 5% (A) tres veces
por semana, mientras que Sanguinaria canadensis + cloruro de zinc (X) se aplico cada cuatro dıas despues
de una fase de inicio diaria de seis dıas. El tratamiento continuo hasta la remision clınica o durante un
maximo de 45 semanas, con un largo perıodo de seguimiento (media de 34 meses). Se volvieron a tomar
biopsias de sarcoides antes de finalizar el tratamiento y en el seguimiento si el propietario dio su consenti-
miento.
Resultados – se registro remision completa en el 84,4% (A) y el 75,0% (X) de los tumores. Se registro
recaıda en el 7,3% (A) y el 21,4% (X). Se observo remision espontanea en el 1,9% de los tumores no trata-
dos. No se detecto ningun efecto sistemico sobre los tumores no tratados. Durante el tratamiento fueron
frecuentes diversos grados de reaccion inflamatoria local.
Conclusiones y relevancia clınica – Ambos tratamientos se consideraron efectivos y seguros. Los tumo-
res mas peque~nos respondieron mas favorablemente al tratamiento. La tasa de recidiva fue baja y no se
observo en biopsias repetidas de sarcoides antes de finalizar el tratamiento.
Zusammenfassung
Hintergrund – Equine Sarkoide sind weltweit die h€aufigsten Hautneoplasien bei Pferden. Obwohl einige
Behandlungsformen existieren, ist keine davon gleichbleibend effektiv und ein Wiederauftreten kommt
h€aufig vor.
Ziele – Eine Evaluierung der Wirksamkeit und Sicherheit von topisch angewendeter Imiquimod 5% Creme
und Sanguinaria canadensis + Zinkchlorid zur Behandlung von equinen Sarkoiden und eine Untersuchung
m€oglicher systemischer Wirkungen auf entfernter gelegene unbehandelte Sarkoide.
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Tiere/Tumore – F€unfundzwanzig Pferde in Privatbesitz mit einer Gesamtzahl von 164 Tumoren wurden in
die Studie aufgenommen. F€unfundsiebzig Tumore wurden behandelt und 107 Tumore blieben unbehan-
delt.
Methoden und Materialien – Es wurden Biopsien von mindestens einem Tumor pro Pferd genommen
und der Rest wurde anhand des klinischen Erscheinungsbildes als wahrscheinliche Sarkoide diagnostiziert.
Es wurde Imiquimod 5% (A) dreimal w€ochentlich aufgetragen, w€ahrend Sanguinaria canadensis + Zinkchlo-
rid (X) jeden vierten Tag nach einer sechst€agigen t€aglich aufgetragenen Eingangsphase, angewendet
wurde. Die Behandlung wurde bis zur klinischen Remission oder f€ur ein Maximum von 45 Wochen weiter-
gef€uhrt, mit einer langen Follow-Up Periode (durchschnittlich 34 Monate). Es wurden erneut Biopsien von
Sarkoiden vor Ende der Therapie genommen und beim Follow-Up wenn der Besitzer dazu sein Ein-
verst€andnis gab.
Ergebnisse – Es wurde bei 84,4% (A) und 75,0% (X) eine v€ollige Remission der Tumore festgehalten. Ein
Wiederauftreten wurde bei 7,3% (A) und bei 21,4% (X) festgestellt. Es wurde bei 1,9% der unbehandelten
Tumore eine spontane Remission beobachtet. Es wurde keine systemische Wirkung auf unbehandelte
Tumore gesehen. W€ahrend der Behandlung traten h€aufig lokale entz€undliche Reaktionen in unterschiedli-
chem Ausmaß auf.
Schlussfolgerungen und klinische Relevanz – Beide Behandlungen wurden als wirksam und sicher
betrachtet. Kleinere Tumore reagierten besser auf die Behandlung. Die R€uckfallsrate war niedrig und




目的 – ウマサルコイド治療に対する外用イミキモド5％クリームおよびSanguinaria canadensis +塩化亜鉛の
有効性および安全性を評価し、未治療のサルコイドに対する全身への影響の可能性を調査する。





























Contexto – Sarcoides equinos s~ao as neoplasias cutâneas mais prevalentes em cavalos em todo o mundo.
Embora varios tratamentos estejam disponıveis, nenhum e consistentemente eficaz e a recorrência e
comum.
Objetivos – Avaliar a eficacia e seguranca do creme topico de imiquimod 5% e Sanguinaria canadensis +
cloreto de zinco para o tratamento de sarcoides equinos e investigar possıveis efeitos sistêmicos em sar-
coides distantes n~ao tratados.
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Animais/Tumores – Vinte e cinco cavalos de clientes com um total de 164 tumores foram incluıdos no
estudo. Cinquenta e sete tumores foram tratados e 107 tumores foram deixados sem tratamento.
Metodos e materiais – As biopsias foram retiradas de no mınimo um tumor por cavalo e o restante foi
diagnosticado com base na aparência clınica compatıvel com sarcoide. Imiquimod 5% (A) foi aplicado três
vezes por semana, enquanto Sanguinaria canadensis + cloreto de zinco (X) foi aplicado a cada quatro dias
apos uma fase de iniciac~ao de seis dias com uso diario. O tratamento continuou ate a remiss~ao clınica ou
por um maximo de 45 semanas, com um longo perıodo de acompanhamento (media de 34 meses). As
biopsias dos sarcoides foram refeitas antes do termino do tratamento e no acompanhamento, se o pro-
prietario desse consentimento.
Resultados – Remiss~ao completa foi registrada em 84,4% (A) e 75,0% (X) dos tumores. Recidiva foi regis-
trada em 7,3% (A) e 21,4% (X). Remiss~ao espontânea foi observada em 1,9% dos tumores n~ao tratados.
Nenhum efeito sistêmico em tumores n~ao tratados foi detectado. Durante o tratamento, varios graus de
reac~ao inflamatoria local foram comuns.
Conclus~oes e relevância clınica – Ambos os tratamentos foram considerados eficazes e seguros. Tumo-
res menores responderam mais favoravelmente ao tratamento. A taxa de recidiva foi baixa e n~ao obser-
vada em biopsias repetidas de sarcoides antes do termino do tratamento.
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